Incannex Healthcare Limited
Incannex Healthcare Limited (IXHL) Financial Performance & Income Statement Overview
Review Incannex Healthcare Limited (IXHL) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Incannex Healthcare Limited (IXHL) Income Statement & Financial Overview
Analyze Incannex Healthcare Limited’s IXHL earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $12000.00 | $12000.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $12000.00 | $12000.00 | $0.00 | $0.00 |
| Gross Profit Ratio | $1.00 | $1.00 | $0.00 | $0.00 |
| R&D Expenses | $1.41M | $4.36M | $2.64M | $1.71M |
| SG&A Expenses | $3.60M | $5.40M | $5.34M | $2.48M |
| Operating Expenses | $5.02M | $9.76M | $7.98M | $4.19M |
| Total Costs & Expenses | $5.02M | $9.76M | $7.98M | $4.19M |
| Interest Income | $28000.00 | $40000.00 | $20000.00 | $0.00 |
| Interest Expense | $171000.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $719000.00 | $62000.00 | $12000.00 | $1000.00 |
| EBITDA | -$5.004M | -$6.40M | -$5.24M | -$4.19M |
| EBITDA Ratio | -$417.00 | -$533.17 | $0.00 | |
| Operating Income | -$5.004M | -$9.74M | -$7.98M | -$4.19M |
| Operating Income Ratio | -$417.00 | -$812.00 | $0.00 | |
| Other Income/Expenses (Net) | -$890000.00 | $3.31M | $2.74M | $20000.00 |
| Income Before Tax | -$5.89M | -$6.43M | -$5.24M | -$4.17M |
| Income Before Tax Ratio | -$491.17 | -$535.92 | $0.00 | |
| Income Tax Expense | $0.00 | $30000.00 | $0.00 | $0.00 |
| Net Income | -$5.89M | -$6.46M | -$5.24M | -$4.17M |
| Net Income Ratio | -$491.17 | -$538.42 | $0.00 | |
| EPS | -$0.33 | -$0.38 | -$0.33 | -$0.26 |
| Diluted EPS | -$0.33 | -$0.38 | -$0.33 | -$0.26 |
| Weighted Avg Shares Outstanding | $17.62M | $17.04M | $15.87M | $15.87M |
| Weighted Avg Shares Outstanding (Diluted) | $17.62M | $17.04M | $15.87M | $15.87M |
Financial performance has remained strong, with revenue growing from $0.00 in Q4 2023 to $12000.00 in Q2 2025. Gross profit continued to perform well, with margins at 100% in the latest quarter. Operating income reached -$5.004M in Q2 2025, holding a steady -41700% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$5.004M. Net income rose to -$5.89M, keeping EPS at -$0.33. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan